HOME > LATEST

LATEST

BUSINESS Sato Enters Smoking Cessation Market via Nicotinell Tie-Up with Dr. Reddy’s

January 27, 2026
BUSINESS Top Court Rejects Samsung Challenge to Patent-Linkage Disclosures in Eylea Biosimilar Case

January 27, 2026
BUSINESS Quviviq, Dayvigo Top 3 Promotion Channels in December: Intage

January 27, 2026
BUSINESS Ajinomoto Builds Presence in ADC CDMO Business with Proprietary Technology

January 27, 2026
COLUMN AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

January 27, 2026
BUSINESS Leqembi Iqlik Now under FDA Review for Initiation Phase

January 26, 2026
BUSINESS Regeneron Japan Launches Scholarship for STEM-Oriented High School Students

January 26, 2026
BUSINESS JCR Expects Strong Returns from Recently In-Licensed DMD Drug: CEO

January 26, 2026
BUSINESS Solasia to Grant MAAB Rights to Antiemetic Drug in China

January 26, 2026
BUSINESS Toho Seeks Additional Disclosure from 3D over Proposed Share Purchases

January 26, 2026
REGULATORY Chuikyo OKs Health Coverage for Optune Lua, CDx for Inluriyo and Elevidys

January 26, 2026
REGULATORY Japan to Bolster Reimbursement Incentives for Biosimilars in FY2026 Fee Revision

January 26, 2026
REGULATORY Japan Panel OKs AbbVie’s Aquipta, Ipsen’s Sohonos, and Novo’s IcoSema for Approval

January 26, 2026
BUSINESS J&J Seeks Pediatric UC Indication for Stelara in Japan

January 26, 2026
BUSINESS Will Unlisted AGs Rush for June Listing or Be Left on Ice?

January 23, 2026
REGULATORY Japan’s 1st Xolair Biosimilar Likely from Celltrion as JAN Is Assigned

January 23, 2026
REGULATORY DPP Vows to Scrap Off-Year Drug Price Revisions in Election Platform

January 23, 2026
REGULATORY Japan Starts Review on Scope of Drugs Eligible for Immunization Use, with Beyfortus in Focus

January 23, 2026
ORGANIZATION Off-Year Drug Price Revisions Run Counter to Innovation, JPMA Exec Says

January 23, 2026
BUSINESS Enhertu Reels in 6th China Indication in Second-Line Gastric Cancer

January 23, 2026

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…